| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6,363 | |||
| Restricted cash | 6 | |||
| Prepaid expenses and other current assets | 2,134 | |||
| Total current assets | 8,503 | |||
| Total assets | 8,503 | |||
| Accounts payable | 3,028 | |||
| Accrued expenses | 1,236 | |||
| Advances from collaboration partners, net of debt discount | 11,823 | |||
| Current portion of long-term debt | 0 | |||
| Accrued interest on debt | 0 | |||
| Total current liabilities | 16,087 | |||
| Common stock, 0.01 par value per share, 500,000,000 shares authorized, 5,072,935 and 4,790,239 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 51 | |||
| Additional paid-in capital | 296,699 | |||
| Accumulated deficit | -304,334 | |||
| Total stockholders' deficit | -7,584 | |||
| Total liabilities and stockholders' deficit | 8,503 | |||
Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. (ELOX)